生血宁片治疗维持性血液透析患者贫血的临床观察  

Clinical Observation on Shengxuening Treating Anemia in Hemodialysis Patients

作　　者：杨岳[1,2] 冯胜刚[1,2] 白亚君[1,2] 杜艳彬[1,2] 

机构地区：[1]川北医学院第二临床学院 [2]南充市中心医院肾内科,四川南充637000

出　　处：《华西医学》2011年第11期1646-1648,共3页West China Medical Journal

摘　　要：目的比较生血宁片和多糖铁复合物胶囊两种口服铁剂在治疗维持性血液透析患者肾性贫血中的治疗效果。方法 2008年12月2010年6月间选择40例维持性血液透析贫血患者,随机分为生血宁片组和多糖铁复合物胶囊组,每组20例,观察期为8周。分别检测两组患者用药前及用药后4、8周时血红蛋白、红细胞压积、血清铁蛋白、转铁蛋白饱和度等指标情况。同时两组患者均使用基因重组人促红细胞生成素,按100～120U/(kg.周),分两次皮下注射。结果治疗前两组指标无明显差异,治疗后两组患者的血红蛋白、红细胞压积、血清铁蛋白以及转铁蛋白饱和度较治疗前均显著上升,且两组患者升高的幅度相比,生血宁组升高的幅度更显著。治疗结束时,两组患者不良反应方面的差异无统计学意义。结论两种口服铁剂均能有效地纠正血液透析患者的铁缺乏及贫血状况;生血宁片组的作用更显著,且还具备降低患者促红细胞生成素使用量的作用。Objective To compare the effect of Shengxuening piece and capsule polysaccharide-iron complex on anemia in hemodialysis patients.Methods A total of 40 patients with anemia in maintenance hemodialysis treated between December 2008 and June 2010 were randomly divided into Shengxuening piece group and capsule polysaccharide-iron complex group;the patients were observed for 8 weeks.Hemoglobin（Hb）,hematocrit（Hct）,serum ferritin（SF）,transferrin saturation（TSAT） and other indicators were detected before treatment four and eight weeks after the treatment.While patients were used recombinant human erythropoietin（EPO） according to 100-120 U/（kg·week）,twice subcutaneous injection.Results Before treatment,there was no significant difference between the two groups.Hb,Hct,SF and TSAT increased significantly after treatment in both of the groups and specially in the Shengxuening piece group.After the treatment,the difference in the adverse reaction between the two groups was not significant.Conclusions Both oral iron can effectively correct the hemodialysis patients with iron deficiency and anemia.However,Shengxuening has more significant role and may reduce the use of erythropoietin in patients with hemodialysis.

关 键 词：口服铁 生血宁 血液透析 促红细胞生成素 肾性贫血 

分 类 号：R692.5[医药卫生—泌尿科学]